Atai Life Sciences Cash Flow from Investing Activities 2020-2024 | ATAI

Atai Life Sciences cash flow from investing activities from 2020 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Atai Life Sciences Annual Cash Flow Investing
(Millions of US $)
2023 $-53
2022 $-87
2021 $-81
2020 $-28
2019 $-9
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $0.311B $0.000B
atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $17.403B 10.53
Quest Diagnostics (DGX) United States $15.823B 16.35
DaVita (DVA) United States $11.969B 14.87
Chemed (CHE) United States $8.605B 26.67
Encompass Health (EHC) United States $8.603B 22.02
Elanco Animal Health (ELAN) United States $8.391B 21.77
Option Care Health (OPCH) United States $5.187B 19.63
RadNet (RDNT) United States $4.254B 88.58
Amedisys (AMED) United States $3.103B 21.98
LifeStance Health (LFST) United States $2.817B 0.00
Astrana Health (ASTH) United States $2.304B 31.16
Addus HomeCare (ADUS) United States $1.805B 25.83
U.S Physical Therapy (USPH) United States $1.601B 42.84
Pennant (PNTG) United States $0.673B 35.57
Aveanna Healthcare Holdings (AVAH) United States $0.510B 0.00
Daxor (DXR) United States $0.045B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.028B 0.00
ATI Physical Therapy (ATIP) United States $0.022B 0.00
Psychemedics (PMD) United States $0.015B 0.00
Ontrak (OTRK) United States $0.013B 0.00
Novo Integrated Sciences (NVOS) United States $0.010B 0.00
IMAC Holdings (BACK) United States $0.004B 0.00